- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04236011
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
June 13, 2021 updated by: Weijun Fu, Shanghai Changzheng Hospital
Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in BCMA+ Refractory/Relapsed Multiple Myeloma
This is a single arm, open-label, multi-center prospective study to determine the safety and efficacy of GC012F CAR-T cells in patients diagnosed with BCMA+ refractory/relapsed multiple myeloma (r/r MM).
Study Overview
Detailed Description
The main aim of the study is to determine the safety and efficacy of GC012F in r/r MM.
GC012F is an autologous dual chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) and CD19.
This study comprises of a Screening Phase (less than or equal to [<=] 28 days prior to apheresis) followed by Apheresis (will occur upon enrollment); Treatment Phase including a conditioning regimen followed by infusion of GC012F and post-infusion assessments from Day 1 to Day 84; and a Post-treatment Phase (Day 85 and up to end of the study).
Efficacy will be explored to assessed and safety will be closely monitored during the study.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weijun Fu
- Phone Number: (+86)13816052522
- Email: fuweijun2010@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Shanghai Changzheng Hospital
-
Contact:
- Weijun Fu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have a confirmed prior diagnosis of active multiple myeloma as defined by the updated IMWG criteria;
Diagnosis of MM with relapsed or refractory disease. Definition of Refractory/relapse:
- Have had at least 3 prior lines of therapy or primary refractory as defined by Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Prior therapy should include PI and IMiD. Note: Patients should undergone at least have at least complete 1 cycle treatment in each line. Induction with or without hematopoietic stem cell transplant followed by maintenance therapy is considered a single line of therapy.
- Have had at least 2 prior lines of therapy when refractory to both immunomodulatory drug (IMiD) and proteasome inhibitor(PI) (Refractory was defined by IMWG consensus criteria);
- Estimated life expectancy ≥3 months;
- Hemoglobin ≥ 8.0 g/dL;
- Absolute neutrophil count ≥ 0.75*10E9/L;
- Platelet count ≥ 50*10E9/L;
- Absolute lymphocyte count ≥ 1*10E8/L;
- Liver, kidney and cardiopulmonary functions meet the following requirements: a)Total bilirubin ≤ 2×ULN(except for Gilbert Syndrome); ALT and/or AST ≤3 × ULN; b)clearance of serum creatinine ≥ 40 mL/min, calculated by Cockcroft-Gault; c)Corrected serum calcium ≤ 12.5mg/dL or free ion calcium ≤ 6.5mg/dL(1.6mmol/L);
- Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis;
- Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 100 days after CART cell infusion;
- Subjects must have signed written, informed consent.
Exclusion Criteria:
- Accompanied by other uncontrolled malignancies.There are two exceptions to this criterion: Recepted radical therapy carcinoma without activity within 3 years before screening; and fully treated skin non-melanoma;
- Any situations not benefit for subjects to accept or tolerated to planned therapy or understand informed consent; or any situation in which investigators believe that participation in this study is not in the subject's best interests (e.g., harm to health), or any situation that may prevent, limit or confuse the assessment;
- Convulsion or stoke within past 6 months;
- Any instability of systemic disease within 6 months prior to screening, including but not limited to congestive heart failure (New York heart association (NYHA) classification ≥ III), unstable angina, cerebrovascular accident, or transient cerebral ischemic, myocardial infarction,LEVF< 45% (assessed by an echocardiogram or multi-door circuit scan );
- Patients have central nervous system (CNS) metastases or CNS involvement (including cranial neuropathies or mass lesions and leptomeningeal disease);
- Subjects with positive HBsAg or HBcAb postive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; syphilis primary screening antibody positive;
- Presence or suspicion of fungi, bacteria, viruses or other infections that are uncontrollable or requiring intravenous treatment;
- Activity of autoimmune diseases (such as crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), orhistory of autoimmune disease within the last 3 years;
- Clinical evidence of dementia or changes of mental state.
- Exist of pulmonary fibrosis;
- Allergy subjects or history of severe hypersensitivity;
- Oxygen inhalation requirment to maintain adequate oxygen saturation;
- Surgery (except for local anesthesia surgery) plan 2 weeks before apheresis. during or 2 weeks after CART infusion;
- Chemotherapy forbidden for cyclophosphamide or fludarabine;
- Pregnant or lactating, or planning to have a pregnancy during or within 100 days after treatment;
- Patients who are accounted to be not appropriate for this trail by investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GC012F treatment
BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells.
Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
|
GC012F injection is a autologous dual CAR-T targeted BCMA and CD19.
A single infusion of CART cells will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events after GC012F infusion
Time Frame: up to 24 weeks after GC012F infusion
|
up to 24 weeks after GC012F infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of MRD negative patients after GC012F treatment
Time Frame: 12 weeks, 24 weeks after GC012F infusion
|
12 weeks, 24 weeks after GC012F infusion
|
|
ORR (PR, VGPR, CR and sCR) of patients receive GC012F treatment
Time Frame: 12 weeks, 24 weeks after GC012F infusion
|
12 weeks, 24 weeks after GC012F infusion
|
|
Progression free survival after GC012F treatment
Time Frame: 12 weeks, 24 weeks after GC012F infusion
|
12 weeks, 24 weeks after GC012F infusion
|
|
Copies and cell counts of CAR in blood and bone marrow (if available) after GC012F treatment
Time Frame: Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after GC012F infusion
|
Bone marrows will be collected in weeks 4, 8, 12, 18, 24 after GC012F infusion.
|
Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after GC012F infusion
|
Cytokines in serum after GC012F treatment
Time Frame: Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after GC012F infusion
|
Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after GC012F infusion
|
|
Subset of lymphocytes and ADA in blood after GC012F treatment
Time Frame: Weeks 4, 8, 12, 18, 24 after GC012F infusion
|
Weeks 4, 8, 12, 18, 24 after GC012F infusion
|
|
Replication competent lentivirus (RCL) in blood after GC012F treatment
Time Frame: Weeks 4, 12, 24 after GC012F infusion
|
Weeks 4, 12, 24 after GC012F infusion
|
|
Duration of response after GC012F treatment
Time Frame: 12 weeks, 24 weeks after GC012F infusion
|
12 weeks, 24 weeks after GC012F infusion
|
|
Overall survival after GC012F treatment
Time Frame: 12 weeks, 24 weeks after GC012F infusion
|
12 weeks, 24 weeks after GC012F infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 16, 2020
Primary Completion (ANTICIPATED)
July 31, 2022
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
January 15, 2020
First Submitted That Met QC Criteria
January 18, 2020
First Posted (ACTUAL)
January 22, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 15, 2021
Last Update Submitted That Met QC Criteria
June 13, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- GBF002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on GC012F injection
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingMultiple MyelomaChina
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.Unknown
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
RenJi HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingCAR-T Cell TherapyChina
-
Zhejiang UniversityGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
Gracell Biopharmaceuticals, Inc.RecruitingRelapsed/ Refractory Multiple MyelomaUnited States
-
Gracell Biotechnologies Ltd.Recruiting
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed